What to make of Eisai and Biogen’s latest Alzheimer’s drug data

For the past two months, doctors have debated the significance of surprisingly positive clinical trial results for a closely watched Alzheimer’s disease drug.

But they have had little to go on, knowing only the barest outline of how beneficial treatment with the drug, called lecanemab, actually was for the study participants who received it.